| abstract |
According to the present disclosure, for use in combination with administration of a mutant antibody having a mutation comprising a substitution, deletion, addition or modification of at least one amino acid in the CH1 region, CH2 region, CH3 region, CL region, or framework region. , a pharmaceutical composition, wherein the pharmaceutical composition comprises a cell expressing a chimeric receptor, and the mutant antibody is capable of binding to the extracellular binding domain of the chimeric receptor by interposing a portion containing the mutation in the extracellular binding domain, and The pharmaceutical composition is provided, wherein the external binding domain does not bind to an antibody that does not contain the mutation. |